Dynamic Inc. | Date: 2014-03-17
Systems and methods are provided for controlling infrared radiation (IR) sources of a sauna including tuning IR wavelength-ranges and radiated power-levels of IR sources, and directing IR to locations on a users body. In one illustrative embodiment, a sauna may be provided having adjustable heat sources to emit IR at any wavelength resulting in a desirable radiation treatment for the sauna user. In another illustrative embodiment, a method is provided for tuning IR sources in a sauna.
Dynamic Inc. | Date: 2015-04-05
The present invention is directed to system and method of forecasts, displays, and alerts for localized hail activity. An exemplary method comprises the steps of selecting a region to monitor, receiving meteorological data for that region, processing the meteorological data for storm cell and hail activity in order to determine hail risk activity. The system forecasts the direction of an active storm as well a user position. Probability bands of hail risk activity are created for display. Optionally, an alert is generated when the user position is in or proximate a threshold probability band.
Dynamic Inc. | Date: 2013-06-28
A gyrator feeder that gyrates a dispensing member to uniformly and circumnavigating dispense material by generating a true circular orbital vibratory motion in the dispensing member by either rotating an offset weight along a vertical central axis of the dispensing member or by positioning vibratory motors diametrical opposite from each other on a gyrator housing and synchronizing the vibratory motors with each other to thereby dispense material.
Dynamic Inc. | Date: 2014-07-15
A system for moving a user between a deck and a floor of a swimming pool is provided. The system includes a rail assembly with rails configured to extend between the deck and the floor of a pool, a seat assembly configured for rolling engagement with the rails, and a drive mechanism configured to translate the seat assembly along the rails.
Agency: National Science Foundation | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 150.00K | Year: 2015
Broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to (1) improve the decision making towards protein therapeutics development (also known as developability), (2) reduce Research and Development costs for the Biotechnology industry in general, (3) improve timelines of new protein therapeutic candidates, thus proceeding to clinical phase trials sooner, (4) resulting in fewer candidate withdrawals from clinical trials, (5) reduce risk associated with protein aggregation and immunogenicity, a potentially fatal outcome; leading to (6) overall quicker times for approval-to-market, and finally (7) a reduction of product recall risk. The market opportunity for protein characterization and identification market by instruments also known as life sciences tools is estimated to be $ 80-85 billion dollars. Our product is an innovative patented technology platform and related services which will support the developability evaluation of new protein therapeutic candidates in the biologics and biosimilars product portfolio. As an additional funding source, we have adopted the production of a high quality aggregate free potential diagnostic candidate biomarker for prostrate and pancreatic cancer to allow for further research and development in other research institutions. Completion of Phase I in the evaluation of formulation conditions of protein therapeutics including monoclonal antibodies (mAbs) will ensure progress towards the development of a high throughput platform for Phase II evaluation. The proposed project will address the current bottleneck of new protein therapeutics within the biologics and biosimilars industry due to protein aggregation. This is the single most prevalent reason that has hampered the release of biotherapeutics into the market. Protein aggregation leads to loss of efficacy and potentially to immunogenicity risks. Formulation is critical to downstream processing, dosing, storage, and delivery of protein therapeutics. Our goal is to test different formulation conditions through the use of Design of Experiment strategies to identify the formulation conditions under which the monoclonal antibody candidate is stable and aggregation free, even under stress. We have designed an innovative patented platform using two dimensional infrared (2D IR) correlation spectroscopy and perturbation correlation (PC) analysis which is accurate, reproducible and does not use probes to determine the mechanism and extent of aggregation, and stability of a mAb. A potential outcome will be the developability assessment of novel candidates ensuring a pipeline of protein therapeutics early in the research and development. If successful, Phase II will involve a high-throughput platform to address the evaluation of protein aggregation in plasma and final IV delivery conditions, for the design of a predictive model for immunogenicity risk assessment.